The British Generics Medicines Association (BGMA) on behalf of Sandoz and other Marketing authorisation holders for the product Rivaroxaban have distributed this prescriber letter intended to minimise the risk of treatment of Rivaroxaban. This prescriber letter was posted ( hard copy) to a total of 81,963 healthcare professionals in May 2024. This is a copy of the letter that was distributed upon launch of this product.